Practical Guide to Hereditary Breast and Ovarian Cancer IV
portes grátis
Practical Guide to Hereditary Breast and Ovarian Cancer IV
Annual Meeting of the Japanese Organization of Hereditary Breast and Ovarian Cancer 2024
Ohno, Shinji; Arai, Masami; Sekine, Masayuki
Springer Verlag, Singapore
03/2026
227
Dura
Inglês
9789819565795
Pré-lançamento - envio 15 a 20 dias após a sua edição
Descrição não disponível.
Part I Advances in Basic Science.- 1. DNA damage response and Immune checkpoint: Recent advances in basic science.- 2. Tissue-specific carcinogenesis induced by BRCA1 deficiency.- Part II Advances in Genetics.- 3. RCA1/2 pathogenic variant-based precision cancer medicine-Insights from C-CAT real world data.- 4. Translating moderate-risk gene data into clinical practice: Focus on CHEK2 germline pathogenic variants.- 5. Large scale functional analysis and evaluation of pathogenicity in BRCA2.- 6. Integrating BRCA1 and BRCA2 pathogenic variants with polygenic risk scores.- Part III Advances in Breast Cancer.- 7. Supporting strategies for HBOC unaffected carriers.- 8. Clinical Practice for Unaffected pathogenic variant carriers of BRCA1/2.- 9. Issue in unaffected carriers from the surveillance out-patients viewpoint.- 10. Present status of clinical practice for HBOC carriers without ovarian cancer.- Part IV Equalization and regional cooperation of clinical practice for hereditary tumor.- 11. Proliferation and regional cooperation in HBOC clinical practice.- 12. Regional cooperation and Equalization in Clinical Practice for hereditary tumor syndrome.- 13. Present status and issue of cooperation of HBOC Clinical Practice in Niigata Prefecture.- 14. Equalization and regional cooperation of clinical practice for hereditary tumor from public data.- 15. Expanding Opportunities and Evolving Challenges in the Genetic Diagnosis and Genetic Counseling of Hereditary Tumors in Japan.- Part V Update on evaluation of homologous recombination deficiency (HRD).- 16. Current Status and Problems of HRD Testing in Ovarian Cancer Treatment.- 17. Timing and Cutoff Line of My Choice HRD Test.- 18. A review of pathological classification by artificial intelligence: a challenge to HRD diagnosis.- Part VI Advances in Assisted Reproductive Technology and PGT-M.- 19. Update on Reproductive Medicine for HBOC.- 20. Progress of Discussion on Indications for PGT in Japan.- Part VII Excellent general presentation.- 21. Knock-in rat model of the BRCA1 pathogenic variant L63X: its basic phenotypes and perspectives for use in cancer prevention research.- 22. BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer.- 23. BRCA2 c.7847C>T (p.Ser2616Phe): A Pathogenic Variant Specific to the Japanese Population.- 24. Prevalence and characteristics of pathogenic variants in BRCA1/2 genes in the Japanese population.- Part VIII JOHBOC registration.- 25. JOHBOC Registration, Registration data of JOHBOC 2023.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Hereditary Breast and Ovarian Cancer;HBOC;Genetic testing;Surveillance;BRCA1;BRCA2;HRD;PARP inhibitors;Risk reducing surgery
Part I Advances in Basic Science.- 1. DNA damage response and Immune checkpoint: Recent advances in basic science.- 2. Tissue-specific carcinogenesis induced by BRCA1 deficiency.- Part II Advances in Genetics.- 3. RCA1/2 pathogenic variant-based precision cancer medicine-Insights from C-CAT real world data.- 4. Translating moderate-risk gene data into clinical practice: Focus on CHEK2 germline pathogenic variants.- 5. Large scale functional analysis and evaluation of pathogenicity in BRCA2.- 6. Integrating BRCA1 and BRCA2 pathogenic variants with polygenic risk scores.- Part III Advances in Breast Cancer.- 7. Supporting strategies for HBOC unaffected carriers.- 8. Clinical Practice for Unaffected pathogenic variant carriers of BRCA1/2.- 9. Issue in unaffected carriers from the surveillance out-patients viewpoint.- 10. Present status of clinical practice for HBOC carriers without ovarian cancer.- Part IV Equalization and regional cooperation of clinical practice for hereditary tumor.- 11. Proliferation and regional cooperation in HBOC clinical practice.- 12. Regional cooperation and Equalization in Clinical Practice for hereditary tumor syndrome.- 13. Present status and issue of cooperation of HBOC Clinical Practice in Niigata Prefecture.- 14. Equalization and regional cooperation of clinical practice for hereditary tumor from public data.- 15. Expanding Opportunities and Evolving Challenges in the Genetic Diagnosis and Genetic Counseling of Hereditary Tumors in Japan.- Part V Update on evaluation of homologous recombination deficiency (HRD).- 16. Current Status and Problems of HRD Testing in Ovarian Cancer Treatment.- 17. Timing and Cutoff Line of My Choice HRD Test.- 18. A review of pathological classification by artificial intelligence: a challenge to HRD diagnosis.- Part VI Advances in Assisted Reproductive Technology and PGT-M.- 19. Update on Reproductive Medicine for HBOC.- 20. Progress of Discussion on Indications for PGT in Japan.- Part VII Excellent general presentation.- 21. Knock-in rat model of the BRCA1 pathogenic variant L63X: its basic phenotypes and perspectives for use in cancer prevention research.- 22. BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer.- 23. BRCA2 c.7847C>T (p.Ser2616Phe): A Pathogenic Variant Specific to the Japanese Population.- 24. Prevalence and characteristics of pathogenic variants in BRCA1/2 genes in the Japanese population.- Part VIII JOHBOC registration.- 25. JOHBOC Registration, Registration data of JOHBOC 2023.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
